Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24846661 | 0.94 | L3MBTL1 (0.39) | SMN1; SMN2MAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL24846554 | 0.93 | DGAT1 (0.41) | MAPTDGAT1KMT2AMEN1TSHR | |
| SCHEMBL24846068 | 0.93 | DGAT1 (0.41) | MAPTDGAT1KMT2AMEN1TSHR | |
| SCHEMBL24846681 | 0.89 | SMN1; SMN2 (0.42) | SMN1; SMN2GAAMAPTXBP1NPSR1 | |
| SCHEMBL24846664 | 0.83 | L3MBTL1 (0.37) | SMN1; SMN2L3MBTL1DGAT1KMT2AMEN1 | |
| SCHEMBL24846665 | 0.83 | L3MBTL1 (0.37) | SMN1; SMN2L3MBTL1DGAT1KMT2AMEN1 | |
| SCHEMBL24846120 | 0.83 | GAA (0.41) | SMN1; SMN2GAAMAPTXBP1NPSR1 | |
| SCHEMBL24846062 | 0.82 | DGAT1 (0.43) | MAPTDGAT1KMT2AMEN1TSHR | |
| SCHEMBL24846089 | 0.82 | DGAT1 (0.43) | MAPTDGAT1KMT2AMEN1TSHR | |
| SCHEMBL24846671 | 0.82 | DGAT1 (0.40) | SMN1; SMN2GAAMAPTXBP1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | SMN1; SMN2 4282/4885GAA 709/4885MAPT 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.